
Trinity Biotech plc
TRIBNASDAQHealthcareMedical - Specialties
Regular session
$10.0001
−$0.5999 · -5.66%
TRIB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
82
Deep Value
Momentum
19
Strong Down
Sentiment
53
Mixed
Risk resilience
29
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTrinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- Headquarters
- IE
- CEO
- John Gillard
- Listed since
- Oct 21, 1992
- Employees
- 287
Market position
Day range
Current $10.0001
52-week range
Current $10.0001
- Open
- $10.48
- Previous close
- $10.60
- Volume
- 365.42
- 0.01× average
- Average volume
- 39.98K
- Average daily volume
- Market cap
- 202.51M USD
- Beta
- 0.99
- Market reference 1
- 50-day average
- $12.2398
- -18.30% below average
- 200-day average
- $20.2695
- -50.66% below average
Financials
Financial snapshot
Latest / TTMFinancial health
- Altman Z-score
- -1.85
- Piotroski F-score
- 3 of 9
TRIB news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$33.0003
2015 complete year+120.0% since 2011
$15.0002
2,011
$22.5002
2,012
$30.0003
2,013
$33.0003
2,014
$33.0003
2,015
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 5, 2015 | $0.22Annual | Jun 9, 2015 | Jul 1, 2015 |
Dividend | Jun 6, 2014 | $0.22Annual | Jun 10, 2014 | Jul 1, 2014 |
Dividend | Jun 6, 2013 | $0.20Annual | Jun 10, 2013 | Jul 1, 2013 |
Dividend | Jun 6, 2012 | $0.15Annual | Jun 8, 2012 | Jun 22, 2012 |
Dividend | Jun 7, 2011 | $0.10Semi-Annual | Jun 9, 2011 | Jun 23, 2011 |
Ex-dividend Jun 5, 2015
$0.22
Annual
Record Jun 9, 2015 · Payment Jul 1, 2015
Ex-dividend Jun 6, 2014
$0.22
Annual
Record Jun 10, 2014 · Payment Jul 1, 2014
Ex-dividend Jun 6, 2013
$0.20
Annual
Record Jun 10, 2013 · Payment Jul 1, 2013
Ex-dividend Jun 6, 2012
$0.15
Annual
Record Jun 8, 2012 · Payment Jun 22, 2012
Ex-dividend Jun 7, 2011
$0.10
Semi-Annual
Record Jun 9, 2011 · Payment Jun 23, 2011
TRIB peers
Continue in GoAI
Research TRIBresearch.disclaimer











